ROUND ROCK, Texas — Benuvia Operations LLC, a global contract development and manufacturing organization, has entered into licensing and supply agreements with Medra Brasil Medicamentos LTDA, a distributor of pharmaceutical medicinal cannabis products.
Under the terms of the licensing agreement, Medra Brasil will become the exclusive supplier for SYNDROS (dronabinol), oral solution, CII in the country of Brazil following approval by the Brazilian Health Regulatory Agency (Anvisa). SYNDROS (dronabinol) is the first and only FDA-approved CII tetrahydrocannabinol (THC) liquid cannabinoid used in adults to treat Chemotherapy Induced Nausea and Vomiting (CINV) and Anorexia Associated Weight Loss and Aids (AAWLA).
“We are thrilled to announce our first out-licensing partnership with Medra Brasil to bring SYNDROS to the people of Brazil,” commented Terry Novak, CEO of Benuvia. “This is an important milestone for Benuvia as we expand our global partnerships to further commercialize SYNDROS and all our cannabinoid and psychedelic products and services.”
For Amanda Sá, CEO of Medra Brasil, the licensing agreement will be a milestone in the use of medicinal cannabis in conditions associated with cancer and AIDS. “More and more people are becoming aware that cannabis medications bring numerous benefits to patients. It is a path of no return.”
Benuvia has also signed a supply agreement with Medra Brasil to support the development of new Medra Brasil CBD products. Under the terms of the agreement, Benuvia will become a key Medra supplier.
Edegar Epaminondas, CEO of Medra USA, emphasizes that the partnership with Benuvia is another significant step in the company’s history, which has been building a strong foundation in the Brazilian market. “Our priority is to bring more new technologies, research development, and contribute to the debureaucratization of access to treatment in Brazil.”
About Benuvia Operations LLC
Benuvia Operations LLC is a global Contract Development and Manufacturing Organization that helps pharmaceutical and biotech companies deliver life-changing therapies to patients in need. The company provides end-to-end development and manufacturing services for Active Pharmaceutical Ingredients (APIs) and finished dosage products and has extensive experience with cannabinoids, psychedelics, and other controlled substances. Benuvia operates an 83,000 square foot manufacturing facility in Round Rock, Texas, that can produce Schedule I-V compounds, offering comprehensive solutions for companies throughout the entire drug development lifecycle—from API synthesis and clinical trial supply to commercial production.
About Medra Brasil Medicamentos LTDA
Medra Brasil Medicamentos is an importer and distributor of pharmaceuticals, cosmetics, and health products, with a special focus on medicinal cannabis. With one of the largest portfolios of medicinal cannabis in the country, the company offers a variety of products, from medications to cosmetics, all carefully selected to meet consumers’ needs.
The pillars of Medra Brasil include investment in research, education of healthcare professionals, and care in customer service. The company is dedicated to bringing innovative and effective solutions to the Brazilian market, aiming to improve the health and well-being of its clients. In addition to its operations in Brazil, Medra also operates in the United States through Medra USA, expanding its reach and strengthening its presence in the international market. Its commitment to quality and innovation is evident in its meticulous approach and continuous investment in new products and quality partnerships.
